Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02775903 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
A Phase 2 study of Myelodysplastic Syndromes and Leukemia, Myeloid, Acute, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 213
- Enrollment target
- 20
- Study locations
NCT02775903 is a Phase 2 study of Myelodysplastic Syndromes and Leukemia, Myeloid, Acute that has completed, run by Celgene. The registered enrollment target is 213 participants, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02775903, a Phase 2 study of Myelodysplastic Syndromes and Leukemia, Myeloid, Acute, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 213 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of subcutaneous azacitidine in combination with durvalumab as compared with subcutaneous azacitidine alone in adults with previously untreated, higher risk MDS who are not eligible for HSCT or in adults ≥ 65 years old with previously untreated AML who are not eligible for HSCT, with intermediate or poor cytogenetic risk.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- DRUG Azacitidine
Study Locations (20)
Other
- Medizinische Universitat Graz - Graz
- Medizinische Universitat Innsbruck - Innsbruck
- Elisabethinen Hospital Linz - Linz
- Salzburger Landkliniken St. Johanns-Spital - Salzburg
- Hanusch Krankenhaus der Stadt Wien - Vienna
- Local Institution - 653 - Vienna
- AKH Wien - Wein
- Cliniques Universitaires St-Luc - Brussels
Florida
- University of Florida - Gainesville
- Moffitt Cancer Center - Tampa
New York
- Roswell Park Cancer Institute - Buffalo
- Icahn School of Medicine at Mount Sinai - New York
Connecticut
- Yale Cancer Center - New Haven
District of Columbia
- Georgetown University Hospital - Washington D.C.
Illinois
- University of Chicago - Chicago
New Jersey
- Hackensack University Medical Center - Hackensack
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2016-06-03 |
| Est. Completion | 2021-12-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02775903
The ClinicalTrials.gov registry entry for NCT02775903 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (25% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT02775903 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT02775903 about?
NCT02775903 is a clinical study titled "An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)". The primary objective of this study is to evaluate the efficacy of subcutaneous azacitidine in combination with durvalumab as compared with subcutaneous azacitidine alone in adults with previously untreated, higher risk MDS who are not eligible for HSCT or in adults ≥ 65 years old with previously un...
What is the current status of trial NCT02775903?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 213 participants. The study started on 2016-06-03. Estimated completion is 2021-12-27.
What conditions does trial NCT02775903 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute.
What interventions are being tested in trial NCT02775903?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Azacitidine (DRUG).
Who is sponsoring clinical trial NCT02775903?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02775903 being conducted?
This trial has 20 study locations across Connecticut, District of Columbia, Florida, Illinois, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.